Sanofi’s SAR446523 Receives Orphan Drug Designation for Multiple Myeloma, Paving Way for Novel Treatment
Sanofi has announced a significant regulatory milestone for its investigational therapy SAR446523, a monoclonal antibody targeting GPRC5D, after the U.S. Food and Drug Administration (FDA) granted it orphan drug designation…